| Title | MANAGEMENT OF ALTERED HYDROCORTISONE PHARMACOKINETICS IN A BOY WITH CONGENITAL ADRENAL HYPERPLASIA USING A CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION. |
| Author(s) | Bryan SM, Honour JW, Hindmarsh PC |
| Institution | Developmental Endocrinology Research Group, Institute of Child Health, University College London; and Clinical Biochemistry, University College London Hospitals, London, United Kingdom. |
| Source | J Clin Endocrinol Metab 2009 Jun 30. |
| Abstract | Background: Conventional hydrocortisone dosing schedules do not mimic the normal circadian rhythm of cortisol making it difficult to optimise treatment in congenital adrenal hyperplasia (CAH). Case Details: We report a 14.5 year old boy with CAH who had reduced bioavailability (42% (normal 80% orally and 100% by intramuscular route) and increased clearance (half-life 50 mins (normal range 70-100 mins) of oral doses of hydrocortisone leading to ambient serum 17 hydroxyprogesterone (17OHP) concentrations of 400 nmol/l (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/l (7.1 ng/ml). Intervention: Using a continuous but variable subcutaneous hydrocortisone infusion (CSHI) via an insulin pump rapid control of his CAH was attained with a normal cortisol circadian profile. Average daily hydrocortisone dose was 17.4-18.6 mg/m(2) which produces on average 24h serum cortisol and 17OHP concentrations of 316 nmol/l (115 ng/ml) and 4.3 nmol/l (1.4 ng/ml) respectively. Therapy has been maintained over 4 years with suppression of normal adrenal androgen production and normal progression through puberty.
Conclusions: CSHI may prove a valuable adjunct to therapy for CAH particularly in patients requiring high doses or oral hydrocortisone and in those with abnormal hydrocortisone pharmacokinetics. |
| Language | ENG |
| Pub Type(s) | JOURNAL ARTICLE
|
| PubMed ID | 19567522 |
